ID   VGFR2_HUMAN             Reviewed;        1356 AA.
AC   P35968; O60723; Q14178;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   02-NOV-2010, entry version 125.
DE   RecName: Full=Vascular endothelial growth factor receptor 2;
DE            Short=VEGFR-2;
DE            EC=2.7.10.1;
DE   AltName: Full=Fetal liver kinase 1;
DE            Short=FLK-1;
DE   AltName: Full=Kinase insert domain receptor;
DE   AltName: Full=Protein-tyrosine kinase receptor flk-1;
DE   AltName: CD_antigen=CD309;
DE   Flags: Precursor;
GN   Name=KDR; Synonyms=FLK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Yin L.Y., Wu Y., Patterson C.;
RT   "Full length human KDR/flk-1 sequence.";
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Umbilical vein;
RA   Yu Y., Whitney R.G., Sato J.D.;
RT   "Coding region for human VEGF receptor KDR (VEGFR-2).";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-1356, AND VARIANT GLU-848.
RC   TISSUE=Umbilical vein;
RX   MEDLINE=92019839; PubMed=1656371;
RA   Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L.,
RA   Shows T.B.;
RT   "Identification of a new endothelial cell growth factor receptor
RT   tyrosine kinase.";
RL   Oncogene 6:1677-1683(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   MEDLINE=96032749; PubMed=7559454; DOI=10.1074/jbc.270.39.23111;
RA   Patterson C., Perrella M.A., Hsieh C.-M., Yoshizumi M., Lee M.-E.,
RA   Harber E.;
RT   "Cloning and functional analysis of the promoter for KDR/flk-1, a
RT   receptor for vascular endothelial growth factor.";
RL   J. Biol. Chem. 270:23111-23118(1995).
RN   [5]
RP   FUNCTION.
RX   MEDLINE=93038639; PubMed=1417831; DOI=10.1016/0006-291X(92)90483-2;
RA   Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D.,
RA   Armellino D.C., Gospodarowicz D., Boehlen P.;
RT   "Identification of the KDR tyrosine kinase as a receptor for vascular
RT   endothelial cell growth factor.";
RL   Biochem. Biophys. Res. Commun. 187:1579-1586(1992).
RN   [6]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=10590123; DOI=10.1128/JVI.74.1.344-353.2000;
RA   Mitola S., Soldi R., Zanon I., Barra L., Gutierrez M.I., Berkhout B.,
RA   Giacca M., Bussolino F.;
RT   "Identification of specific molecular structures of human
RT   immunodeficiency virus type 1 Tat relevant for its biological effects
RT   on vascular endothelial cells.";
RL   J. Virol. 74:344-353(2000).
RN   [7]
RP   INTERACTION WITH SHB.
RX   PubMed=15026417; DOI=10.1074/jbc.M312729200;
RA   Holmqvist K., Cross M.J., Rolny C., Haegerkvist R., Rahimi N.,
RA   Matsumoto T., Claesson-Welsh L., Welsh M.;
RT   "The adaptor protein shb binds to tyrosine 1175 in vascular
RT   endothelial growth factor (VEGF) receptor-2 and regulates VEGF-
RT   dependent cellular migration.";
RL   J. Biol. Chem. 279:22267-22275(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1054 AND TYR-1059, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [9]
RP   PHOSPHORYLATION AT TYR-951; TYR-1175 AND TYR-1214, AND
RP   DEPHOSPHORYLATION BY PTPRB.
RX   PubMed=19136612; DOI=10.1096/fj.08-123810;
RA   Mellberg S., Dimberg A., Bahram F., Hayashi M., Rennel E., Ameur A.,
RA   Westholm J.O., Larsson E., Lindahl P., Cross M.J., Claesson-Welsh L.;
RT   "Transcriptional profiling reveals a critical role for tyrosine
RT   phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial
RT   cell morphogenesis.";
RL   FASEB J. 23:1490-1502(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 806-1171, FUNCTION,
RP   PHOSPHORYLATION AT TYR-1059, AND MASS SPECTROMETRY.
RX   PubMed=10368301; DOI=10.1016/S0969-2126(99)80042-2;
RA   McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V.,
RA   Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.-C.,
RA   Villafranca J.E., Appelt K.;
RT   "Crystal structure of the kinase domain of human vascular endothelial
RT   growth factor receptor 2: a key enzyme in angiogenesis.";
RL   Structure 7:319-330(1999).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) OF 806-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15837294; DOI=10.1016/j.bmcl.2005.03.034;
RA   Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M.,
RA   Philippe R.J., Shibahara M., Liu W., Sato H., Wang L., Nolte R.T.;
RT   "Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 15:2203-2207(2005).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 815-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=17253678; DOI=10.1021/jm061107l;
RA   Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S.,
RA   Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M.,
RA   Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R.,
RA   Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F.,
RA   Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., Zhao H.;
RT   "Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-
RT   triazine Tie-2 kinase inhibitor.";
RL   J. Med. Chem. 50:611-626(2007).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 806-1171 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND FUNCTION.
RX   PubMed=18529047; DOI=10.1021/jm8001185;
RA   Peifer C., Selig R., Kinkel K., Ott D., Totzke F., Schaechtele C.,
RA   Heidenreich R., Roecken M., Schollmeyer D., Laufer S.;
RT   "Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-
RT   indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial
RT   growth factor receptor (VEGF-R) inhibitors.";
RL   J. Med. Chem. 51:3814-3824(2008).
RN   [14]
RP   VARIANT HCI SER-1147.
RX   PubMed=11807987; DOI=10.1002/gcc.10028;
RA   Walter J.W., North P.E., Waner M., Mizeracki A., Blei F.,
RA   Walker J.W.T., Reinisch J.F., Marchuk D.A.;
RT   "Somatic mutation of vascular endothelial growth factor receptors in
RT   juvenile hemangioma.";
RL   Genes Chromosomes Cancer 33:295-303(2002).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-275 AND ARG-873.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-2; MET-136; GLY-248; ILE-297;
RP   VAL-462; HIS-472; ARG-482; ARG-539; MET-689; ASN-814 AND THR-1065.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [17]
RP   VARIANT HCI SUSCEPTIBILITY ARG-482.
RX   PubMed=18931684; DOI=10.1038/nm.1877;
RA   Jinnin M., Medici D., Park L., Limaye N., Liu Y., Boscolo E.,
RA   Bischoff J., Vikkula M., Boye E., Olsen B.R.;
RT   "Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2
RT   signaling in infantile hemangioma.";
RL   Nat. Med. 14:1236-1246(2008).
CC   -!- FUNCTION: Receptor for VEGF or VEGFC. Has a tyrosine-protein
CC       kinase activity. The VEGF-kinase ligand/receptor signaling system
CC       plays a key role in vascular development and regulation of
CC       vascular permeability. In case of HIV-1 infection, the interaction
CC       with extracellular viral Tat protein seems to enhance angiogenesis
CC       in Kaposi's sarcoma lesions.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with MYOF (By similarity). Interacts with SHB;
CC       upon VEGF activation. Interacts with HIV-1 Tat.
CC   -!- INTERACTION:
CC       P35916:FLT4; NbExp=1; IntAct=EBI-1005487, EBI-1005467;
CC       O14786:NRP1; NbExp=1; IntAct=EBI-1005487, EBI-1187100;
CC       P29350:PTPN6; NbExp=1; IntAct=EBI-1005487, EBI-78260;
CC       P12931:SRC; NbExp=2; IntAct=EBI-1005487, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- PTM: Dephosphorylated by PTPRB.
CC   -!- DISEASE: Defects in KDR are associated with susceptibility to
CC       hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign,
CC       highly proliferative lesions involving aberrant localized growth
CC       of capillary endothelium. They are the most common tumor of
CC       infancy, occurring in up to 10% of all births. Hemangiomas tend to
CC       appear shortly after birth and show rapid neonatal growth for up
CC       to 12 months characterized by endothelial hypercellularity and
CC       increased numbers of mast cells. This phase is followed by slow
CC       involution at a rate of about 10% per year and replacement by
CC       fibrofatty stroma.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC   -!- SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like)
CC       domains.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF035121; AAB88005.1; -; mRNA.
DR   EMBL; AF063658; AAC16450.1; -; mRNA.
DR   EMBL; L04947; AAA59459.1; -; mRNA.
DR   EMBL; X61656; CAA43837.1; -; mRNA.
DR   EMBL; X89776; CAA61916.1; -; Genomic_DNA.
DR   IPI; IPI00021396; -.
DR   PIR; JC1402; JC1402.
DR   RefSeq; NP_002244.1; -.
DR   UniGene; Hs.479756; -.
DR   PDB; 1VR2; X-ray; 2.40 A; A=806-1171.
DR   PDB; 1Y6A; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1Y6B; X-ray; 2.10 A; A=806-1171.
DR   PDB; 1YWN; X-ray; 1.71 A; A=806-1171.
DR   PDB; 2OH4; X-ray; 2.05 A; A=806-1171.
DR   PDB; 2P2H; X-ray; 1.95 A; A=815-1171.
DR   PDB; 2P2I; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 2QU5; X-ray; 2.95 A; A=815-1171.
DR   PDB; 2QU6; X-ray; 2.10 A; A/B=815-1171.
DR   PDB; 2RL5; X-ray; 2.65 A; A=815-1171.
DR   PDB; 2X1W; X-ray; 2.70 A; L/M/N/O=120-326.
DR   PDB; 2X1X; X-ray; 3.10 A; R=120-326.
DR   PDB; 3B8Q; X-ray; 2.75 A; A/B=815-1171.
DR   PDB; 3B8R; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3BE2; X-ray; 1.75 A; A=815-1171.
DR   PDB; 3C7Q; X-ray; 2.10 A; A=806-1171.
DR   PDB; 3CJF; X-ray; 2.15 A; A=806-1168.
DR   PDB; 3CJG; X-ray; 2.25 A; A=806-1168.
DR   PDB; 3CP9; X-ray; 2.50 A; A/B=815-1171.
DR   PDB; 3CPB; X-ray; 2.70 A; A/B=815-1171.
DR   PDB; 3CPC; X-ray; 2.40 A; A/B=815-1171.
DR   PDB; 3DTW; X-ray; 2.90 A; A/B=815-1171.
DR   PDB; 3EFL; X-ray; 2.20 A; A/B=815-1171.
DR   PDB; 3EWH; X-ray; 1.60 A; A=815-1171.
DR   PDB; 3KVQ; X-ray; 2.70 A; A=657-764.
DR   PDBsum; 1VR2; -.
DR   PDBsum; 1Y6A; -.
DR   PDBsum; 1Y6B; -.
DR   PDBsum; 1YWN; -.
DR   PDBsum; 2OH4; -.
DR   PDBsum; 2P2H; -.
DR   PDBsum; 2P2I; -.
DR   PDBsum; 2QU5; -.
DR   PDBsum; 2QU6; -.
DR   PDBsum; 2RL5; -.
DR   PDBsum; 2X1W; -.
DR   PDBsum; 2X1X; -.
DR   PDBsum; 3B8Q; -.
DR   PDBsum; 3B8R; -.
DR   PDBsum; 3BE2; -.
DR   PDBsum; 3C7Q; -.
DR   PDBsum; 3CJF; -.
DR   PDBsum; 3CJG; -.
DR   PDBsum; 3CP9; -.
DR   PDBsum; 3CPB; -.
DR   PDBsum; 3CPC; -.
DR   PDBsum; 3DTW; -.
DR   PDBsum; 3EFL; -.
DR   PDBsum; 3EWH; -.
DR   PDBsum; 3KVQ; -.
DR   ProteinModelPortal; P35968; -.
DR   SMR; P35968; 31-546, 234-747, 547-756.
DR   DIP; DIP-486N; -.
DR   DIP; DIP-5741N; -.
DR   IntAct; P35968; 7.
DR   MINT; MINT-127732; -.
DR   STRING; P35968; -.
DR   PhosphoSite; P35968; -.
DR   PRIDE; P35968; -.
DR   Ensembl; ENST00000263923; ENSP00000263923; ENSG00000128052.
DR   GeneID; 3791; -.
DR   KEGG; hsa:3791; -.
DR   UCSC; uc003has.1; human.
DR   CTD; 3791; -.
DR   GeneCards; GC04M055944; -.
DR   H-InvDB; HIX0031357; -.
DR   HGNC; HGNC:6307; KDR.
DR   HPA; CAB004028; -.
DR   MIM; 191306; gene.
DR   MIM; 602089; phenotype.
DR   Orphanet; 91415; Familial capillary hemangioma.
DR   PharmGKB; PA30086; -.
DR   HOVERGEN; HBG053432; -.
DR   InParanoid; P35968; -.
DR   OMA; QDYRSPF; -.
DR   OrthoDB; EOG9S4S2G; -.
DR   PhylomeDB; P35968; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; s1p_s1p1_pathway; S1P1 pathway.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Reactome; REACT_12529; Signaling by VEGF.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   NextBio; 14887; -.
DR   ArrayExpress; P35968; -.
DR   Bgee; P35968; -.
DR   CleanEx; HS_KDR; -.
DR   Genevestigator; P35968; -.
DR   GermOnline; ENSG00000128052; Homo sapiens.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; TAS:BHF-UCL.
DR   GO; GO:0005178; F:integrin binding; IPI:BHF-UCL.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; TAS:BHF-UCL.
DR   GO; GO:0005021; F:vascular endothelial growth factor receptor...; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; TAS:BHF-UCL.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0010595; P:positive regulation of endothelial cell mig...; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell pro...; IMP:BHF-UCL.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; IDA:BHF-UCL.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   InterPro; IPR007110; Ig-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR001824; Tyr_prot_kinase_rcpt_3_CS.
DR   InterPro; IPR009136; Tyr_prot_kinase_VEGFR2_rcpt.
DR   InterPro; IPR009134; Tyr_prot_kinase_VEGFR_rcpt_N.
DR   Gene3D; G3DSA:2.60.40.10; Ig-like_fold; 8.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF298; Tyr_prot_kinase_VEGFR2_rcpt; 1.
DR   Pfam; PF07679; I-set; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF07686; V-set; 1.
DR   PRINTS; PR01832; VEGFRECEPTOR.
DR   PRINTS; PR01834; VEGFRECEPTR2.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50835; IG_LIKE; 5.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Complete proteome;
KW   Developmental protein; Differentiation; Glycoprotein;
KW   Host-virus interaction; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     19       Potential.
FT   CHAIN        20   1356       Vascular endothelial growth factor
FT                                receptor 2.
FT                                /FTId=PRO_0000016771.
FT   TOPO_DOM     20    764       Extracellular (Potential).
FT   TRANSMEM    765    789       Helical; (Potential).
FT   TOPO_DOM    790   1356       Cytoplasmic (Potential).
FT   DOMAIN       46    110       Ig-like C2-type 1.
FT   DOMAIN      141    207       Ig-like C2-type 2.
FT   DOMAIN      224    320       Ig-like C2-type 3.
FT   DOMAIN      328    414       Ig-like C2-type 4.
FT   DOMAIN      421    548       Ig-like C2-type 5.
FT   DOMAIN      551    660       Ig-like C2-type 6.
FT   DOMAIN      667    753       Ig-like C2-type 7.
FT   DOMAIN      834   1162       Protein kinase.
FT   NP_BIND     840    848       ATP (By similarity).
FT   ACT_SITE   1028   1028       Proton acceptor (By similarity).
FT   BINDING     868    868       ATP (By similarity).
FT   SITE       1175   1175       Interaction with SHB (By similarity).
FT   MOD_RES     951    951       Phosphotyrosine.
FT   MOD_RES    1054   1054       Phosphotyrosine.
FT   MOD_RES    1059   1059       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1175   1175       Phosphotyrosine.
FT   MOD_RES    1214   1214       Phosphotyrosine.
FT   CARBOHYD     46     46       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     66     66       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD     96     96       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    143    143       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    158    158       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    245    245       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    318    318       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    374    374       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    395    395       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    511    511       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    523    523       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    580    580       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    613    613       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    619    619       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    631    631       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    675    675       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    704    704       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    721    721       N-linked (GlcNAc...) (Potential).
FT   VARIANT       2      2       Q -> R (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042053.
FT   VARIANT     136    136       V -> M (in dbSNP:rs35636987).
FT                                /FTId=VAR_042054.
FT   VARIANT     248    248       A -> G (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042055.
FT   VARIANT     275    275       R -> L (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036126.
FT   VARIANT     297    297       V -> I (in dbSNP:rs2305948).
FT                                /FTId=VAR_022071.
FT   VARIANT     462    462       L -> V (in dbSNP:rs56286620).
FT                                /FTId=VAR_042056.
FT   VARIANT     472    472       Q -> H (in dbSNP:rs1870377).
FT                                /FTId=VAR_020353.
FT   VARIANT     482    482       C -> R (in HCI susceptibility; expression
FT                                of FLT1 in hemangioma endothelial cells
FT                                is markedly reduced and KDR activity is
FT                                increased compared to controls; low FLT1
FT                                expression in hemangioma cells is caused
FT                                by reduced activity of a pathway
FT                                involving ITGB1, ANTXR1, KDR and
FT                                NFATC2IP; the mutation predicts to result
FT                                in loss-of-function and disruption of the
FT                                normal association of these molecules;
FT                                dbSNP:rs34231037).
FT                                /FTId=VAR_042057.
FT   VARIANT     539    539       G -> R (in dbSNP:rs55716939).
FT                                /FTId=VAR_042058.
FT   VARIANT     689    689       T -> M (in dbSNP:rs34038364).
FT                                /FTId=VAR_042059.
FT   VARIANT     814    814       D -> N (in dbSNP:rs35603373).
FT                                /FTId=VAR_042060.
FT   VARIANT     848    848       V -> E (in dbSNP:rs1139776).
FT                                /FTId=VAR_046679.
FT   VARIANT     873    873       G -> R (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                /FTId=VAR_036127.
FT   VARIANT     952    952       V -> I (in dbSNP:rs13129474).
FT                                /FTId=VAR_046680.
FT   VARIANT    1065   1065       A -> T (in dbSNP:rs56302315).
FT                                /FTId=VAR_042061.
FT   VARIANT    1147   1147       P -> S (in HCI; somatic mutation).
FT                                /FTId=VAR_063147.
FT   CONFLICT      2      2       Q -> E (in Ref. 2; AAC16450).
FT   CONFLICT    772    772       A -> T (in Ref. 3; AAA59459/CAA43837).
FT   CONFLICT    787    787       R -> G (in Ref. 3; AAA59459/CAA43837).
FT   CONFLICT    835    835       K -> N (in Ref. 3; AAA59459/CAA43837).
FT   CONFLICT   1347   1347       S -> T (in Ref. 3; AAA59459/CAA43837).
FT   HELIX       824    827
FT   HELIX       831    833
FT   STRAND      834    841
FT   STRAND      844    855
FT   STRAND      858    860
FT   STRAND      862    870
FT   HELIX       876    892
FT   STRAND      901    905
FT   STRAND      907    910
FT   STRAND      913    917
FT   HELIX       924    929
FT   TURN        930    933
FT   HELIX      1002   1021
FT   HELIX      1031   1033
FT   STRAND     1034   1036
FT   STRAND     1042   1044
FT   HELIX      1068   1071
FT   HELIX      1074   1077
FT   HELIX      1084   1099
FT   HELIX      1115   1120
FT   HELIX      1133   1142
FT   HELIX      1147   1149
FT   HELIX      1153   1167
SQ   SEQUENCE   1356 AA;  151527 MW;  59E7C44B05CFEBB3 CRC64;
     MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD
     WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD
     YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD
     SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE
     KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS
     DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP
     EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP
     PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY
     PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE
     RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT
     PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT
     VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR
     NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL
     LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL
     GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN
     LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK
     RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA
     SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR
     VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML
     DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS
     CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS
     GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS
     SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV
//
